Skip to main content

Main menu

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Other Publications
    • NeuroSciences Journal

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Saudi Medical Journal
  • Other Publications
    • NeuroSciences Journal
  • My alerts
  • Log in
Saudi Medical Journal

Advanced Search

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Follow psmmc on Twitter
  • Visit psmmc on Facebook
  • RSS
NewsWHO News Release
Open Access

WHO and United States Food and Drug Administration extend the CRP-Lite pilot

Saudi Medical Journal July 2024, 45 (7) 753;
  • Article
  • eLetters
  • Info & Metrics
  • References
  • PDF
Loading

19 June 2024 - Following the initial pilot phase, the World Health Organization (WHO) and the United States Food and Drug Administration (FDA) agreed to further extend the Collaborative Registration Procedure-Lite (CRP-Lite) pilot that helps faster registration of medicines in countries and accelerate access to HIV treatment.

The CRP-Lite pilot was started in 2018 and led to the facilitation of the prequalification of two HIV products – HA741 (ritonavir 25 mg tablets, Cipla) and HA743 (abacavir/lamivudine 600 mg/300 mg tablets, Cipla) – using minimally redacted FDA reports shared with the WHO Prequalification Team.

FDA provides the WHO Prequalification Programme with reviews of HIV medicines that have been either approved or tentatively approved by the agency under the USA President’s Emergency Plan for AIDS Relief (PEPFAR). Use of existing FDA reviews helps WHO expedite its assessments of the medicines, producing reports which can then be shared with regulators in resource-limited countries to speed up their own regulatory review processes, which makes life-saving drugs available to patients faster.

Currently, FDA and WHO-supported CRP-Lite process is proposed only for HIV antiretroviral medicines for an additional three HIV products. If the results are encouraging, the model could be expanded for other therapeutic areas in the future.

The CRP-Lite pilot process builds on the collaborative registration procedure (CRP) introduced by WHO in 2013. With CRP, product registration time in countries were reduced from a few years to less than 90 days, for over 1200 registrations. The CRP is currently used in 66 countries across all regions and one regional economic community (CARICOM).

Most regulatory authorities in low-income countries are under-resourced and over-stretched, resulting in long delays in approvals of medicines that are desperately needed by patients. Initiatives such as CRP and CRP-Lite are vital to improve regulatory efficiency and to deliver life-saving medicines to communities as rapidly as possible.

Available from: https://www.who.int/news/item/19-06-2024-who-and-united-states-food-and-drug-administration-extend-the-crp-lite-pilot

  • Copyright: © Saudi Medical Journal

This is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work.

PreviousNext
Back to top

In this issue

Saudi Medical Journal: 45 (7)
Saudi Medical Journal
Vol. 45, Issue 7
1 Jul 2024
  • Table of Contents
  • Cover (PDF)
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Saudi Medical Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
WHO and United States Food and Drug Administration extend the CRP-Lite pilot
(Your Name) has sent you a message from Saudi Medical Journal
(Your Name) thought you would like to see the Saudi Medical Journal web site.
Citation Tools
WHO and United States Food and Drug Administration extend the CRP-Lite pilot
Saudi Medical Journal Jul 2024, 45 (7) 753;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
WHO and United States Food and Drug Administration extend the CRP-Lite pilot
Saudi Medical Journal Jul 2024, 45 (7) 753;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • eLetters
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • WHO launches first-ever guidelines on meningitis diagnosis, treatment and care
  • WHO issues its first-ever reports on tests and treatments for fungal infections
  • Many pregnancy-related complications going undetected and untreated – WHO
Show more WHO News Release

Similar Articles

CONTENT

  • home

JOURNAL

  • home

AUTHORS

  • home
Saudi Medical Journal

© 2025 Saudi Medical Journal Saudi Medical Journal is copyright under the Berne Convention and the International Copyright Convention.  Saudi Medical Journal is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work. Electronic ISSN 1658-3175. Print ISSN 0379-5284.

Powered by HighWire